article thumbnail

Conducting Healthcare Investment Research with Expert Insights

Alpha Sense BI

Industry and Market Analysis – Analyzing broader industry trends and market dynamics that can affect healthcare companies’ performance by assessing factors such as regulatory changes, technological advancements, demographic shifts, and healthcare policies.

article thumbnail

Debunking 5 Popular Expert Network Myths

Alpha Sense BI

Expert networks are a critical tool for market intelligence and are leveraged by professionals to gain firsthand knowledge of specialized industries, companies, and markets. Calculate the return on investment (ROI) of your market intelligence by using our ROI calculator.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AlphaSense Expands in APAC with Launch of New Regional Hub in Singapore

Alpha Sense BI

Singapore is home to some of the largest regional companies and multinationals in Asia and is a global hub for tech and innovation—making it a natural fit as a regional hub for AlphaSense that will complement our existing innovation and engineering hubs in India, and offices around the world. Read the full press release here.

article thumbnail

US Manufacturers Regain Bullishness Amid Q1 Rebound in Production Activity

ArchIntel

While the United States manufacturing sector took a hit from COVID-19-spawned disruptions, it is important to note that the industry churns out the goods needed to sustain the needs and wants of the world’s largest consumer market. She spent two years at KLA as market intelligence manager. As of 2019, there were some 12.8

article thumbnail

Know where your competitors are conducting clinical trials!

Sedulo

2 Next, we grouped pharmaceutical sponsors/collaborators by their Scrip 100 industry rankings into two groups: top 20 pharma and all other pharma. Our Approach to this Analysis: We started by analyzing pharma-sponsored clinical trials, 1 initiated between 2018 and 2022, for only unapproved primary immuno-oncology (IO) drugs.

Biotech 52
article thumbnail

Market and Competitive Intelligence Solution Poised to Redefine CI/MI Paradigms

Contify

The right to challenge assumptions (A) An internal market analyst should be expected to challenge internal assumptions that are not robust. The analyst should be drawing on a variety of both primary and secondary intelligence. How often are we surprised by a non-direct competitor launching a radical innovation?

article thumbnail

Pharmacy Benefit Manager Transparency Act: What it Means and What Pharma Execs Are Saying

Alpha Sense BI

Under these programs, “prescription drug spending accounts for a significant portion of national pharmaceutical spending, which totaled $577 billion in 2021, and supply-chain complexity has complicated efforts to track the flow of these dollars.” So maybe the PBMs are to blame.